| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5856346 | CHIESI | Short-acting dihydropyridines |
Jan, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5739152 | CHIESI | Pharmaceutical emulsion |
Apr, 2015
(9 years ago) | |
| US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(7 years from now) | |
| US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(7 years from now) | |
| US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(7 years from now) | |
Cleviprex is owned by Chiesi.
Cleviprex contains Clevidipine.
Cleviprex has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Cleviprex are:
- US5739152
- US5856346
Cleviprex was authorised for market use on 01 August, 2008.
Cleviprex is available in emulsion;intravenous dosage forms.
Cleviprex can be used as cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.
Drug patent challenges can be filed against Cleviprex from 01 August, 2012.
The generics of Cleviprex are possible to be released after 10 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2013 |
Drugs and Companies using CLEVIDIPINE ingredient
NCE-1 date: 01 August, 2012
Market Authorisation Date: 01 August, 2008
Treatment: Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable
Dosage: EMULSION;INTRAVENOUS
CLEVIPREX family patents
